Shorter Versus Longer-term Antibiotic Treatments for Community-Acquired Pneumonia in Children: A Meta-analysis

Author:

Gao Ya12,Liu Ming12,Yang Kelu3,Zhao Yunli24,Tian Jinhui15,Pernica Jeffrey M26,Guyatt Gordon27

Affiliation:

1. aEvidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China

2. bDepartments of Health Research Methods, Evidence, and Impact

3. cDepartment of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, KU Leuven, Leuven, Belgium

4. dNational Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China

5. eKey Laboratory of Evidence-based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China

6. fDivision of Infectious Diseases, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada

7. gMedicine

Abstract

CONTEXT The optimal duration of antibiotic treatment of children with community-acquired pneumonia (CAP) remains unclear. OBJECTIVES This study aimed to compare the efficacy and safety of shorter versus longer duration of antibiotic treatment of children with CAP. DATA SOURCES We searched Medline, Embase, CENTRAL, and CINAHL. STUDY SELECTION Randomized clinical trials comparing shorter (≤5 days) with longer duration antibiotic treatments in children with CAP. DATA EXTRACTION Paired reviewers independently extracted data and we performed random-effects meta-analyses to summarize the evidence. RESULTS Sixteen trials with 12 774 patients, treated as outpatients with oral antibiotics, proved eligible. There are probably no substantial differences between shorter-duration and longer-duration antibiotics in clinical cure (odds ratio 1.01, 95% confidence interval [CI] 0.87 to 1.17; risk difference [RD] 0.1%; moderate certainty), treatment failure (relative risk [RR] 1.06, 95% CI 0.93 to 1.21; RD 0.3%; moderate certainty), and relapse (RR 1.12, 95% CI 0.92 to 1.35; RD 0.5%; moderate certainty). Compared with longer-duration antibiotics, shorter-duration antibiotics do not appreciably increase mortality (RD 0.0%, 95% CI −0.2 to 0.1; high certainty), and probably have little or no impact on the need for change in antibiotics (RR 1.03, 95% CI 0.72 to 1.47; RD 0.2%; moderate certainty), need for hospitalization (RD −0.2%, 95% CI −0.9 to 0.5; moderate certainty), and severe adverse events (RD 0.0%, 95% CI −0.2 to 0.2; moderate certainty). LIMITATIONS For some outcomes, evidence was lacking. CONCLUSIONS Duration of antibiotic therapy likely makes no important difference in patient-important outcomes. Healthcare workers should prioritize the use of shorter-duration antibiotics for children with CAP treated as outpatients with oral antibiotics.

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology and Child Health

Reference65 articles.

1. Epidemiology and etiology of childhood pneumonia;Rudan;Bull World Health Organ,2008

2. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries;Rudan;J Glob Health,2013

3. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals;Liu;Lancet,2016

4. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis;McAllister;Lancet Glob Health,2019

5. Ambulatory visit rates and antibiotic prescribing for children with pneumonia, 1994–2007;Kronman;Pediatrics,2011

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. The Current Evidence for Short-Course Antibiotics in Pediatric Community Acquired Pneumonia;Current Treatment Options in Pediatrics;2023-11-15

2. How Long Antibiotic Treatment Is Needed for Community-acquired Pneumonia in Children?;Pediatric Infectious Disease Journal;2023-10-20

3. La pagina gialla;Medico e Bambino;2023-06-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3